Novel Point-of-Care Diagnostic Test for SARS-CoV-2 (COVID-19) : Evaluation of a Novel Point-of-Care Diagnostic Test for SARS-CoV-2
PRIMARY OBJECTIVE:I. To evaluate the clinical performance of a novel point-of-care diagnostic test for detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the disease called coronavirus disease 19 (COVID-19).SECONDARY OBJECTIVES:I. To compare the clinical performance of provider-collected nasopharyngeal samples with self-collected nasal swab, cheek swab, and saliva sample using the novel SARS-CoV-2 diagnostic test.II. To measure viral load and evaluate the role of viral load in COVID-19 severity.OUTLINE:Participants undergo collection of nasopharyngeal (back of the nose) samples by a medical provider and self-collection of oral, saliva, and nasal samples.After completion of study, participants are followed up at 1 month..
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
ClinicalTrials.gov - (2021) vom: 22. Dez. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
610 |
|---|
| Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: August 14, 2020, Last downloaded: ClinicalTrials.gov processed this data on January 03, 2022, Last updated: January 05, 2022 |
|---|
| Study ID: |
NCT04513990 |
|---|---|
| Veröffentlichungen zur Studie: |
|
| fisyears: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
CTG003488322 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG003488322 | ||
| 003 | DE-627 | ||
| 005 | 20230425192929.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210408s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG003488322 | ||
| 035 | |a (UBBS_Klinische_Studien)NCT04513990 | ||
| 035 | |a (UBBS_Klinische_Studien)2020-0318 | ||
| 035 | |a (UBBS_Klinische_Studien)NCI-2020-03470 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Novel Point-of-Care Diagnostic Test for SARS-CoV-2 (COVID-19) |b Evaluation of a Novel Point-of-Care Diagnostic Test for SARS-CoV-2 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: August 14, 2020, Last downloaded: ClinicalTrials.gov processed this data on January 03, 2022, Last updated: January 05, 2022 | ||
| 520 | |a PRIMARY OBJECTIVE:I. To evaluate the clinical performance of a novel point-of-care diagnostic test for detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the disease called coronavirus disease 19 (COVID-19).SECONDARY OBJECTIVES:I. To compare the clinical performance of provider-collected nasopharyngeal samples with self-collected nasal swab, cheek swab, and saliva sample using the novel SARS-CoV-2 diagnostic test.II. To measure viral load and evaluate the role of viral load in COVID-19 severity.OUTLINE:Participants undergo collection of nasopharyngeal (back of the nose) samples by a medical provider and self-collection of oral, saliva, and nasal samples.After completion of study, participants are followed up at 1 month. | ||
| 650 | 2 | |a COVID-19 | |
| 650 | 4 | |a Medical Condition: COVID-19 Infection | |
| 650 | 4 | |a Study Type: Interventional | |
| 650 | 4 | |a Recruitment Status: Active, not recruiting | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2021) vom: 22. Dez. |
| 773 | 1 | 8 | |g year:2021 |g day:22 |g month:12 |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT04513990 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 22 |c 12 | ||